Docetaxel plus cisplatin is effective for patients with metastatic breast cancer resistant to previous anthracycline treatment: a phase II clinical trial

BACKGROUND: Patients with metastatic breast cancer (MBC) are frequently exposed to high cumulative doses of anthracyclines and are at risk of resistance and cardiotoxicity. This phase II trial evaluated the efficacy and toxicity of docetaxel plus cisplatin, as salvage chemotherapy in patients with M...

Descripción completa

Detalles Bibliográficos
Autores principales: Park, Se Hoon, Cho, Eun Kyung, Bang, Soo-Mee, Shin, Dong Bok, Lee, Jae Hoon, Lee, Young Don
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2005
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC553982/
https://www.ncbi.nlm.nih.gov/pubmed/15723709
http://dx.doi.org/10.1186/1471-2407-5-21

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC553982/
https://www.ncbi.nlm.nih.gov/pubmed/15723709
http://dx.doi.org/10.1186/1471-2407-5-21

Ejemplares similares